RVPH News and Press, Reviva Pharmaceuticals Holdings Inc. From 08/17/23

- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17, 2...

2023-08-14 17:17:07 ET Reviva Pharmaceuticals press release ( NASDAQ: RVPH ): Q2 GAAP EPS of -$0.55. As of June 30, 2023, the Company’s cash totaled approximately $11.2 million compared to approximately $18.5 million as of December 31, 2022. For further detail...

- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 - CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSW...

New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podc...

CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...

2023-06-26 06:28:02 ET Reviva Pharmaceuticals Holdings ( NASDAQ: RVPH ) will be added to the Russell Microcap Index, effective after the market opens on Monday, June 26, 2023, following the conclusion of the 2023 Russell indexes annual reconstitution. Source: Press Release ...

CUPERTINO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...

- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation - - Topline data for Phase 3 REC...

CUPERTINO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous ...

2023-05-25 06:46:44 ET Reviva Pharmaceuticals ( NASDAQ: RVPH ) presented preclinical data on brilaroxazine in rat model of idiopathic pulmonary fibrosis (IPF) at the 2023 American Thoracic Society (ATS) International Conference. IPF is a serious condition in which the lun...